Evidence map›Paper›PMID 39347412›Full record

ArticleHeliyon2024

Deficiency of

Kaiyu Guan, Minjie Ye, Anqi Guo, Xiaoyu Chen, Yunfeng Shan, Xi Li

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kaiyu GuanZhejiang Clinical Research Center for Mental Disorders, The Affiliated Kangning Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Minjie YeZhejiang Clinical Research Center for Mental Disorders, The Affiliated Kangning Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Anqi GuoZhejiang Clinical Research Center for Mental Disorders, The Affiliated Kangning Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.
Xiaoyu ChenThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Yunfeng ShanThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Xi LiZhejiang Clinical Research Center for Mental Disorders, The Affiliated Kangning Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Liver-expressed antimicrobial peptide-2 (LEAP2) is identified as an endogenous antagonist and inverse agonist of the growth hormone secretagogue receptor type 1a (GHSR1a), its effect on the GHSR1a is contrary to the role of GHRELIN. Growth hormone (GH) is a crucial hormone for early development. Previous studies report that LEAP2 dose-dependently attenuates ghrelin-induced GH secretion, and Leap2-knockout mice exhibit increased plasma GH levels after GHRELIN administration. Clinical data revealed a possible correlation between LEAP2 and height development. However, the role of LEAP2 in early development remains unclear. This study aimed to investigate the role of LEAP2 in early development using Method: We analyzed the conservation of LEAP2 peptide across multiple species and generated Result: Our data demonstrate that zebrafish with a knockout of the Conclusion: In general, this study demonstrates that LEAP2 regulates the expression of GH during early development, particularly influencing body length.

Indexed as

DevelopmentGrowth hormone (GH)Leap2Somatic growthZebrafish

Identifiers

PMID39347412
PMCPMC11437977

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.